TNNI3K

TNNI3K is a cardiomyocyte-specific dual-specificity (Tyr and Ser/Thr) kinase that localizes to the sarcomere Z disc and functions as a central regulator of cardiac conduction, myofilament contractility, cardiomyocyte ploidy, and the cardiac stress response (PMID:23085512, PMID:31589606, PMID:23236294). It phosphorylates cardiac troponin I at Ser43 and Thr143 to enhance cardiomyocyte contraction, and its kinase activity—dependent on N-terminal ANK domain-mediated autophosphorylation and negatively regulated by the C-terminal domain and the interactor AOP-1—drives p38 MAPK-dependent mitochondrial oxidative stress during ischemia/reperfusion injury and controls mononuclear diploid cardiomyocyte frequency and proliferative capacity (PMID:23369981, PMID:17660584, PMID:18205602, PMID:24132636, PMID:31589606, PMID:37597489). Gain-of-function TNNI3K missense variants with enhanced autophosphorylation cause familial dilated cardiomyopathy, cardiac conduction disease, and supraventricular tachycardia, whereas loss-of-function variants underlie congenital junctional ectopic tachycardia (PMID:30010057, PMID:37199186, PMID:38424693). Loss of TNNI3K kinase activity also produces concentric ventricular remodeling with impaired calcium dynamics, diminished PKA signaling, and increased cardiac inflammation during viral myocarditis (PMID:33084860, PMID:41745317).

1. 2007 Medium

   Establishing that TNNI3K is a dual-specificity kinase whose activity depends on ANK-domain-mediated autophosphorylation and dimerization, with negative regulation by its C-terminal domain and the interactor AOP-1, resolved the basic enzymatic mechanism and regulatory logic of this previously uncharacterized cardiac kinase.

   Evidence In vitro kinase assays with domain deletions/mutations; yeast two-hybrid, co-IP, and kinase inhibition assays with AOP-1

   PMID:17660584 PMID:18205602

   Open questions at the time

   • No in vivo validation of domain-deletion effects
   • AOP-1 inhibitory mechanism not structurally resolved
   • Substrate specificity in vivo unknown
2. 2007 Medium

   Identifying MEF2C as an essential transcriptional activator of the TNNI3K promoter explained the gene's cardiomyocyte-restricted expression pattern.

   Evidence Promoter truncation, EMSA supershift, and MEF2C antisense knockdown in cardiac cell lines

   PMID:18021318

   Open questions at the time

   • No chromatin-level in vivo validation (ChIP)
   • Other transcription factors that cooperate with MEF2C not identified
3. 2008 Medium

   Demonstrating that TNNI3K overexpression promotes cardiomyocyte differentiation, enhances contractile function, and suppresses p38/JNK-mediated apoptosis established a pro-survival and pro-contractile role in the cardiac context.

   Evidence P19CL6 differentiation assay, intramyocardial transplantation in MI mouse model, apoptosis signaling readouts

   PMID:18552163

   Open questions at the time

   • Overexpression-only design; no loss-of-function control
   • Signaling intermediates between TNNI3K and p38/JNK not defined
4. 2009 High

   Showing that TNNI3K transgenic overexpression worsens disease progression in both calsequestrin-transgenic and pressure-overload heart failure models revealed that excessive TNNI3K activity is deleterious during cardiac stress.

   Evidence Double-transgenic (TNNI3K/Csq) and pressure-overload mouse models with echocardiography and survival analysis

   PMID:19763165

   Open questions at the time

   • Downstream effectors not identified
   • Dose–response relationship between expression level and pathology not defined
5. 2012 High

   Linking TNNI3K expression level to PR interval duration and confirming this via transgenic overexpression established TNNI3K as a modulator of atrioventricular conduction, connecting kinase function to cardiac electrophysiology.

   Evidence eQTL mapping, mRNA–PR interval correlation, transgenic overexpression with ECG in DBA/2J mice

   PMID:23236294

   Open questions at the time

   • Cellular mechanism of conduction modulation (ion channel targets) not identified
   • Not tested in human conduction disease at this time
6. 2012 High

   Demonstrating that kinase-dead TNNI3K fails to drive cardiac remodeling in pressure overload and localizing the protein to the Z disc proved that kinase catalytic activity—not scaffolding—is the disease-relevant function and placed TNNI3K at the sarcomere.

   Evidence Wild-type vs. kinase-dead TNNI3K transgenic mice under pressure overload; immunostaining; in vitro kinase assay and proteomics

   PMID:23085512

   Open questions at the time

   • Direct phosphorylation substrates at the Z disc beyond cTnI not identified
7. 2013 Medium

   Identifying cardiac troponin I as a direct TNNI3K substrate phosphorylated at Ser43/Thr143 (and Ser22/Ser23 in a parallel study), with functional effects on cardiomyocyte contraction, provided the first defined substrate–function link for this kinase.

   Evidence Co-IP, in vitro kinase assay with site-specific antibodies, overexpression/knockdown in adult rat ventricular myocytes, contraction measurements; parallel transgenic mouse study with phosphoamino acid analysis

   PMID:23369981 PMID:23472207

   Open questions at the time

   • Discrepancy between studies on exact cTnI phosphorylation sites (Ser43/Thr143 vs. Ser22/Ser23) not reconciled
   • Structural basis of TNNI3K–cTnI interaction unknown
8. 2013 High

   Establishing that TNNI3K drives ischemia/reperfusion injury through p38 MAPK activation and mitochondrial superoxide production—reversible by pharmacologic TNNI3K inhibition—defined a druggable pathogenic pathway and validated TNNI3K as a therapeutic target.

   Evidence Mouse I/R model, mitochondrial superoxide and p38 phosphorylation measurements, small-molecule TNNI3K inhibitors reducing infarct size

   PMID:24132636

   Open questions at the time

   • Direct substrate linking TNNI3K to p38 activation not identified
   • Long-term in vivo efficacy and selectivity of inhibitors not tested
9. 2015 High

   Solving the crystal structure of TNNI3K in complex with a purine-based inhibitor revealed the kinase active-site architecture and enabled rational inhibitor design.

   Evidence X-ray crystallography of TNNI3K–inhibitor complex

   PMID:26355916

   Open questions at the time

   • No structure of full-length TNNI3K or of the ANK domain
   • No substrate-bound co-crystal structure
10. 2018 Medium

    Demonstrating that the TNNI3K p.Glu768Lys variant has enhanced autophosphorylation and co-segregates with familial supraventricular tachycardia, conduction disease, and cardiomyopathy in three families established gain-of-function as a human disease mechanism.

    Evidence In vitro autophosphorylation assay of mutant vs. wild-type; genetic co-segregation in three independent families

    PMID:30010057

    Open questions at the time

    • No in vivo knock-in model of this variant
    • Mechanism by which enhanced autophosphorylation leads to arrhythmia not defined
11. 2019 High

    Showing that kinase-dead knock-in (K489R) phenocopies the Tnni3k null in controlling mononuclear diploid cardiomyocyte frequency—and that common human variants reduce kinase activity—linked TNNI3K kinase activity to cardiomyocyte ploidy and regenerative potential.

    Evidence Kinase-dead knock-in and null mice; in vitro kinase assay of human variant proteins; mononuclear diploid cardiomyocyte quantification

    PMID:31589606

    Open questions at the time

    • Mechanism by which kinase activity controls cytokinesis completion unknown
    • Downstream phosphorylation targets in ploidy regulation not identified
12. 2021 High

    Demonstrating that loss of TNNI3K kinase activity (null, kinase-dead, hypomorphic alleles) causes concentric remodeling, impaired calcium dynamics, and diminished PKA signaling revealed an essential homeostatic role in the adult heart.

    Evidence Three independent Tnni3k alleles with cardiomyocyte morphometry, calcium imaging, contractility, PKA signaling, and echocardiography

    PMID:33084860

    Open questions at the time

    • Direct mechanism linking TNNI3K to PKA pathway not resolved
    • Whether remodeling is cell-autonomous not confirmed
13. 2023 Medium

    Further pathogenic TNNI3K variants with enhanced autophosphorylation reinforced gain-of-function as the dominant disease mechanism for DCM/CCD/SVT, while Tnni3k was shown to influence both S-phase re-entry and cytokinesis completion after injury, extending its role in cardiomyocyte proliferation.

    Evidence Autophosphorylation assays with genetic segregation and UK Biobank burden testing; single-cell ventricular cell-cycle analysis in Tnni3k knockout mice after injury

    PMID:37199186 PMID:37597489

    Open questions at the time

    • No rescue experiments confirming variant causality
    • Cell-cycle targets of TNNI3K not identified
14. 2024 Medium

    Identifying loss-of-function TNNI3K variants underlying congenital junctional ectopic tachycardia revealed that both gain- and loss-of-function of kinase activity cause distinct arrhythmia phenotypes, establishing TNNI3K as a bidirectional regulator of cardiac rhythm.

    Evidence Kinase activity assay of p.Leu577Phe and p.Pro742Leu variants with genetic co-segregation

    PMID:38424693

    Open questions at the time

    • Mechanism by which reduced kinase activity produces junctional ectopic tachycardia not defined
    • No animal model of these specific variants
15. 2026 Medium

    Demonstrating that Tnni3k knockout and kinase-dead mice exhibit increased cardiac macrophage infiltration during viral myocarditis extended the kinase-dependent functions of TNNI3K to anti-inflammatory cardioprotection.

    Evidence Tnni3k knockout and kinase-dead mice infected with CVB3; histological quantification of macrophage infiltration

    PMID:41745317

    Open questions at the time

    • Signaling pathway from TNNI3K to macrophage recruitment not defined
    • Whether effect is cardiomyocyte-autonomous or involves paracrine signaling unknown

• Major open questions include the full phosphoproteome of TNNI3K substrates beyond cTnI, the structural basis of full-length TNNI3K regulation (including ANK domain and dimerization), the direct signaling intermediates linking TNNI3K to p38 MAPK and PKA pathways, and how kinase activity controls cardiomyocyte cytokinesis and ploidy.
• No unbiased phosphoproteomics screen for TNNI3K substrates published
• No full-length TNNI3K crystal structure
• Mechanism connecting TNNI3K kinase activity to cardiomyocyte cell division unknown